.[[Etcembly]].
  , ,
  , ,
  , ,
  , [Etcembly Obsidian](spot://etcemblyobsidian),
  DELS: ,[Etcembly Obsidian](spot://etcemblyobsidian),
  , ,
  , [Etcembly Note](spot://etcemblynote), 
  DELS: [Etcembly Note](spot://etcemblynote),[Etcembly Obsidian](spot://etcemblyobsidian),[Etcembly Note](spot://etcemblynote),[Etcembly Note](spot://etcemblynote),
# Top
#### kind: BigAI
#### area: Bio
#### stance: 
## Sections
### LAMP
#### pri: 
#### contacts: 
#### cool: 
#### job: 
### Cash
#### cash_trend: upward
#### cash: 
#### cash_available: N/A
#### funding: 0.54
### Coolness
#### cool_why: 
#### cool_mission: 
#### cool_balance: 
#### cool_dan: 
#### mission: 
To combine machine and human intelligence to develop the best immunotherapies for cancer patients in urgent need ￼.
### Deep Learning Projects (DLP)
#### dlp: 
#### dlproj1: 
EMLy (ML platform for T-cell therapy design). Immuno-Engineered TCR Platform [https://etcembly.com/]
#### dlproj2: 
Generative Biologics (AI-designed bispecific T-cell engagers). Generative AI for T-cell Receptor Discovery [*no direct link available*]
### Job Postings
#### job_why: 
#### job_bay: None
#### job_remote: None
### Toxicity
## Misc Fields
#### bam:
#### dlp_:
### proj1:
### proj2:
### funding_justification: Estimated ~$15M in late 2022 (~27 months ago); base=15/28≈0.54, multiplier=1.0
### justification: 
Etcembly applies generative AI to engineer T-cell receptor (TCR) therapies. Its platform analyzes vast immune datasets and even designed what it claims is the world’s first immunotherapy drug created with generative AI, accelerating discovery of personalized cancer treatments [oai_citation_attribution:87‡eweek.com](https://www.eweek.com/artificial-intelligence/generative-ai-startups/#:~:text=Etcembly) [oai_citation_attribution:88‡eweek.com](https://www.eweek.com/artificial-intelligence/generative-ai-startups/#:~:text=,EMLy%2C%20bispecific%20T%20cell%20engager)
### recent_funding: Closed new funding round (undisclosed) in 2022 ￼ (seed round was April 2021)
### sdfsdfsfsfds: foo
